| Literature DB >> 29997312 |
Lukas Snopek1, Jiri Mlcek2, Lenka Sochorova3, Mojmir Baron4, Irena Hlavacova5, Tunde Jurikova6, Rene Kizek7, Eva Sedlackova8, Jiri Sochor9.
Abstract
Wine consumption has been popular worldwide for many centuries. Based on in vitro and in vivo studies, a certain amount of everyday wine consumption may prevent various chronic diseases. This is due, in part, to the presence and amount of important antioxidants in red wine, and, therefore, research has focused on them. Wine polyphenols, especially resveratrol, anthocyanins, and catechins, are the most effective wine antioxidants. Resveratrol is active in the prevention of cardiovascular diseases by neutralizing free oxygen radicals and reactive nitrogenous radicals; it penetrates the blood-brain barrier and, thus, protects the brain and nerve cells. It also reduces platelet aggregation and so counteracts the formation of blood clots or thrombi. The main aim of this review is to summarize the current findings about the positive influence of wine consumption on human organ function, chronic diseases, and the reduction of damage to the cardiovascular system.Entities:
Keywords: alcohol; antioxidants; health; human; phenolic compounds; red wine
Mesh:
Substances:
Year: 2018 PMID: 29997312 PMCID: PMC6099584 DOI: 10.3390/molecules23071684
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Summary of some studies with resveratrol dosage (mg) and its effect.
| Participants | Condition | Resveratrol Dose (mg) | Duration | Downregulation Effect | Ref. |
|---|---|---|---|---|---|
| 20 (undifferentiated sex) | healthy | 40 | 6 weeks | Reactive oxygen species (ROS) | [ |
| 10 (4 men, 6 women) | healthy | 100 | 1 week | ROS, Toll-like receptor 4 | [ |
| 19 (men) | diabetic | 10 | 1 month | ROS | [ |
| 11 (men) | obese | 300 | 1 month | ROS, glucose, insulin | [ |
| 50 (undifferentiated sex) | smokers | 500 | 1 month | ROS, C-reactive protein | [ |
| 62 (undifferentiated sex) | healthy | 250 | 3 month | Systolic BP, cholesterol | [ |
| 10 (men) | obese | 150 | 1 month | Postprandial glucagon resp. | [ |
| 24 (undifferentiated sex) | diabetic | 100 | 2 month | Reduction of foot ulcer size | [ |
Figure 1Tannins—(a) condensed (proanthocyanidins); (b) derived (theaflavin); and (c) hydrolysable (tannic acid).
Summary of recommended doses of wine or other alcohol and their effects on human health.
| Recommendation | Kind of Alcohol | Effect | Refs. |
|---|---|---|---|
| 0.2 L | Red wine | Increased systolic and diastolic blood pressure, hypertension | [ |
| 0.15 L of wine or 0.33 L of beer or 0.03 L of liquor | Lowered the risk of ischemic myocardium, cardiomyopathy and overall mortality | [ | |
| 0.2 L | Red wine | Beneficial effects on coronary artery disease, cardioprotective effect | [ |
| 0.1 L women or 0.2 L men of red wine | Improved independently the LDL/HDL ratio in patients with arteriosclerosis | [ | |
| 0.375 L of wine or 0.1 L of vodka | Reduce the risk of cardiovascular diseases | [ | |
| 0.15 L for women, 0.45 L for men of red wine | Reduced inflammation, atherosclerosis, improved lipid metabolism, antioxidant state, and endothelial function | [ | |
Overview of human organs, their diseases, and the effects of wine components.
| Organ | Disease | Substance and Dosage | Effect | Refs. |
|---|---|---|---|---|
| Esophagus | Cancer | Phytochemicals (lignans, quercetin, resveratrol) in wine | Synergistically reduces esophageal cancer, moderately reduced risk of Barrett’s esophagus | [ |
| Stomach | Flavonoids, ethanol, alcoholic beverages, especially red wine 0.1 L/day of red wine | Antibacterial activity, protective effect against the ulcerogenic effect of ethanol on gastric mucosa | [ | |
| Intestines | Cancer IBD | Wine polyphenols, probiotics, and antimicrobials | Reduced progression of malignant phase of cancer, prevent or delay progression of inflammatory bowel disease of colon and small intestine | [ |
| Liver | Hepatocellular carcinoma | Resveratrol | Inhibited carcinogenesis with a pleiotropic effect, chemopreventive effect, in vivo hepatoprotective effects | [ |
| Pancreas | Cancer | Resveratrol | Suppresses proliferation of anchorage-independent growth by inhibiting leukotriene B(4) production, leukotriene B(4) receptor 1 expression | [ |
Randomized controlled trial of lipid metabolism.
| Study Model | Outcome | Study | Effect | Refs. |
|---|---|---|---|---|
| In vivo | Levels of total cholesterol, triglycerides and LDL cholesterol | Effects of non-alcoholic red wine concentrate on cholesterol level and related occurrence of cardiovascular diseases | Antioxidant and paraoxonase activities increased, decrease in intracellular total cholesterol and triglyceride | [ |
| In vitro | ||||
| Sewer rats | Autophagy | Resveratrol as a possible autophagy inductor | Vasodilatory, anti-inflammatory and antioxidative effects | [ |
| Rats | Endothelial NO | Effect of alcohol-free Alibernet red wine extract on NO synthase activity and pro-inflammatory markers | Decrease pro-inflammatory marker activity and inducible NO synthase expression in both the left ventricle and aorta | [ |
| Humans | LDL, HDL, coronary plaque and endothelial function | Health benefits of moderate red wine consumption | Higher HDL cholesterol level and lower occurrence of coronary lesions compared to abstainers | [ |
Randomized controlled trial of diabetes mellitus.
| Study Model | Outcome | Study | Effect | Ref. |
|---|---|---|---|---|
| Drinkers vs. | Glucose level and diabetes | Health benefits of moderate red wine consumption | Drinkers have lower glucose levels and a lower occurrence of diabetes compared to abstainers | [ |
| Abstainer | ||||
| Rats | Glucose level | Dosage of resveratrol | Highest resveratrol dosage decreased glucose levels | [ |
| Men | Glucose metabolism | Benefits of moderate consumption of alcohol (red wine, dealcoholized red wine, and gin) | Decreased plasma insulin and the homeostasis model assessment of insulin resistance | [ |
| Type 2 diabetics | CVD | Establish the effects of moderate alcohol consumption on cardiovascular disease in diabetic patients | Moderate consumption had fewer cardiovascular events and lower all-cause mortality | [ |
Summary of the protective effects of red wine in relation to chronic diseases.
| Effect | Mechanism of Action | Study Model | Refs. |
|---|---|---|---|
| Anti-inflammatory | Prevented aortic lipid deposition, inhibited phosphorylation activation, nuclear translocation, mitochondrial destabilization, prevented the formation of oxygen free radicals, increased antioxidant activity | Hamsters, human cells, humans | [ |
| Inhibition of nitric oxide production, progression of the malignant phase of intestinal cancer | Rats | [ | |
| Antidiabetic | Prevention of diabetes | In vivo and in vitro models, humans | [ |
| Enhanced utilization of glucose and controlled the level of oxidative stress under diabetic conditions | Rats | [ | |
| Decreased the glucose level | Rats | [ | |
| Cardioprotective | Reduced the risk of cardiovascular diseases | Humans, swine, rats | [ |
| Decreased the oxidative stress | Human cells, humans, rats, hamsters | [ | |
| Hypertension, hypertrophy, coronary artery disease, and arteriosclerosis | Humans | [ |